Oncolytic herpes simplex virus propagates tertiary lymphoid structure formation via CXCL10/CXCR3 to boost antitumor immunity

Meng-Jie Zhang , Wen-Ping Lin , Qing Wang , Shuo Wang , An Song , Yuan-Yuan Wang , Hao Li , Zhi-Jun Sun

Cell Proliferation ›› 2025, Vol. 58 ›› Issue (1) : e13740

PDF
Cell Proliferation ›› 2025, Vol. 58 ›› Issue (1) : e13740 DOI: 10.1111/cpr.13740
ORIGINAL ARTICLE

Oncolytic herpes simplex virus propagates tertiary lymphoid structure formation via CXCL10/CXCR3 to boost antitumor immunity

Author information +
History +
PDF

Abstract

Inducing tertiary lymphoid structure (TLS) formation can fuel antitumor immunity. It is necessary to create mouse models containing TLS to explore strategies of TLS formation. Oncolytic herpes simplex virus-1 (oHSV) exhibited intense effects in preclinical and clinical trials. However, the role of oHSV in TLS formation remains to be elucidated. Here, we observed the presence of TLS in 4MOSC1 and MC38 subcutaneous tumour models. Interestingly, oHSV evoked TLS formation, and increased infiltration of B cells and stem-like TCF1+CD8+ T cells proliferation. Mechanistically, oHSV increased the expression of TLS-related chemokines, along with upregulated CXCL10/CXCR3 to facilitate TLS formation. Notably, CXCL10 and CXCR3 were favourable prognostic factors for cancer patients, and closely related with immune cells infiltration. Inhibiting CXCL10/CXCR3 reduced TCF1+CD8+ T cells and granzyme B expression, and impaired oHSV-mediated TLS formation. Furthermore, oHSV-mediated TLS formation revealed superior response and survival rate when combined with αPD-1 treatment. Collectively, these findings indicate that oHSV recruits stem-like TCF1+CD8+ T cells through CXCL10/CXCR3 pathway to propagate TLS formation, and warrants future antitumor immunity development.

Cite this article

Download citation ▾
Meng-Jie Zhang, Wen-Ping Lin, Qing Wang, Shuo Wang, An Song, Yuan-Yuan Wang, Hao Li, Zhi-Jun Sun. Oncolytic herpes simplex virus propagates tertiary lymphoid structure formation via CXCL10/CXCR3 to boost antitumor immunity. Cell Proliferation, 2025, 58(1): e13740 DOI:10.1111/cpr.13740

登录浏览全文

4963

注册一个新账户 忘记密码

References

RIGHTS & PERMISSIONS

2024 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.

AI Summary AI Mindmap
PDF

123

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/